14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MESO vs ABCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas ABCL carries 60.7/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin).
Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (60.7/100 BUY vs. MESO 34.6/100 SELL) and 2.31β · 87% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs ABCL. Trailing 12-month operating profitability (MESO -42.6% vs ABCL -1550.0%) and valuation multiples (MESO N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MESO vs ABCL Key Questions & Quantitative Answers
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas ABCL carries 60.7/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (60.7/100 BUY vs. MESO 34.6/100 SELL) and 2.31β · 87% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $66M for ABCL. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.
ABCL screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus ABCL (-17.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.